BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.

DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.

TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources, ("VVC”), (TSX-V:VVC and ...

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for chronic inflammatory diseases, today announced that David J.

Dec. 2, 2024 — Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease (CHD), according to ...

Dec. 5, 2024 — The fungus that causes coffee wilt disease repeatedly took up segments of DNA from a related fungal pathogen, which contributed to successive ...

NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on ...

Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and ...

DOVER, Del., Nov. 26, 2024 /PRNewswire/ -- Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential ...